ImmuPharma plc (LON:IMM – Get Free Report)’s stock price was up 8.1% during trading on Tuesday . The stock traded as high as GBX 4.05 and last traded at GBX 4.05. 2,067,688 shares were traded during trading, a decline of 27% from the average daily volume of 2,824,305 shares. The stock had previously closed at GBX 3.75.
ImmuPharma Stock Performance
The company has a market cap of £24.02 million, a price-to-earnings ratio of -10.41 and a beta of 3.02. The stock’s fifty day moving average is GBX 4.23 and its two-hundred day moving average is GBX 5.53.
ImmuPharma (LON:IMM – Get Free Report) last released its quarterly earnings results on Wednesday, May 27th. The company reported GBX (0.37) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 398.67%. On average, equities research analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- Catching the AI Wave: DigitalOcean Reels in AI Whales
- Rivian’s 75 Million-Share Offering Turns the R2 Growth Story Into a Dilution Test
- Sony Is Going All-Digital—But Investors Should Watch This Instead
- Scotiabank Sees a New Growth Story for Cloudflare
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
